Taysha Gene Therapies, Inc.
TSHA
$6.86
$0.010.07%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -49.69% | -22.06% | -338.82% | 18.90% | 26.47% |
| Total Depreciation and Amortization | -3.82% | -8.03% | -12.01% | -13.84% | -11.87% |
| Total Amortization of Deferred Charges | -- | -- | -83.04% | -- | -- |
| Total Other Non-Cash Items | 13.66% | 3.57% | 133.98% | -61.76% | -65.20% |
| Change in Net Operating Assets | 68.43% | 56.92% | 93.88% | 33.27% | -36.20% |
| Cash from Operations | -34.15% | -14.61% | -7.14% | -8.97% | -14.89% |
| Capital Expenditure | 37.25% | -97.33% | -23.66% | -15.36% | -461.47% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -16,061.11% | 1,118.18% | 1,928.57% | 102.35% | 100.52% |
| Cash from Investing | -448.32% | -66.39% | 10.88% | 91.38% | 83.46% |
| Total Debt Issued | -- | -- | 26.05% | -- | -- |
| Total Debt Repaid | -- | -- | 5.55% | -- | -- |
| Issuance of Common Stock | 244.65% | 244.07% | 179.86% | 5.57% | -45.26% |
| Repurchase of Common Stock | 56.75% | 56.75% | -35.46% | 5.44% | 5.44% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 27.65% | -82.16% | 60.70% | 75.05% | 58.94% |
| Cash from Financing | 259.21% | 258.08% | 208.65% | 7.56% | -43.94% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,267.96% | 3,788.72% | 2,207.38% | 9.71% | -112.21% |